Q1 Earnings Forecast for ABCL Issued By Leerink Partnrs

AbCellera Biologics Inc. (NASDAQ:ABCL) – Analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of AbCellera Biologics in a report issued on Wednesday, April 16th. Leerink Partnrs analyst P. Souda anticipates that the company will earn ($0.16) per share for the quarter. The consensus estimate for AbCellera Biologics’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for AbCellera Biologics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.17) EPS.

Several other equities research analysts also recently commented on the stock. Benchmark reiterated a “hold” rating on shares of AbCellera Biologics in a research report on Monday, March 3rd. KeyCorp raised their price target on shares of AbCellera Biologics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Stifel Nicolaus reduced their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, February 28th.

AbCellera Biologics Stock Up 1.3 %

Shares of ABCL stock opened at $2.42 on Friday. The business has a fifty day simple moving average of $2.52 and a 200 day simple moving average of $2.77. The company has a market cap of $721.13 million, a P/E ratio of -3.97 and a beta of 0.50. AbCellera Biologics has a twelve month low of $1.89 and a twelve month high of $4.34.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in AbCellera Biologics by 6.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,747 shares of the company’s stock worth $925,000 after buying an additional 21,483 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in AbCellera Biologics in the fourth quarter valued at $265,000. State Street Corp raised its position in AbCellera Biologics by 1.5% during the third quarter. State Street Corp now owns 323,229 shares of the company’s stock valued at $840,000 after purchasing an additional 4,679 shares in the last quarter. HighTower Advisors LLC boosted its holdings in shares of AbCellera Biologics by 577.9% in the 4th quarter. HighTower Advisors LLC now owns 71,086 shares of the company’s stock worth $208,000 after purchasing an additional 60,600 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of AbCellera Biologics by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 62,629 shares of the company’s stock worth $184,000 after purchasing an additional 5,955 shares in the last quarter. Hedge funds and other institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.